Latest Neovasc Inc (NVCIF) Headlines Neovasc,
Post# of 97
Posted On: 03/10/2014 8:30:51 PM
Latest Neovasc Inc (NVCIF) Headlines
Neovasc, an OPKO Investee, Reports Successful First Human Implant of Tiara(TM) Transcatheter Mitral Valve
Business Wire - Mon Feb 03, 8:16AM CST
OPKO Health, Inc. (NYSE:OPK), a multi-national biopharmaceutical and diagnostics company, today reported that Neovasc Inc. (TSXV:NVC), a Vancouver-based company in which OPKO has made a strategic investment, reported that a first-in-human implantation of its Tiara(TM) transcatheter mitral valve was successfully performed on January 30th by physicians at St. Paul's Hospital in Vancouver, BC. The transapical procedure resulted in the elimination of mitral regurgitation (MR) and significantly improved heart function in the patient, without the need for cardiac bypass support and with no procedural complications.
Neovasc receives first US patent for its novel Tiara(TM) transcatheter mitral valve replacement technology
PR Newswire - Wed Nov 13, 6:28AM CST
TSX Venture Exchange: NVC
Neovasc, an OPKO Supported Company, Reports That Reducer(TM) Achieves Primary Endpoint in COSIRA Trial, Significantly Improving Function in Patients with Refractory Angina
Business Wire - Wed Nov 06, 2:51PM CST
OPKO Health, Inc. (NYSE:OPK), a multi-national biopharmaceutical and diagnostics company, today reported that Neovasc Inc. (NVC.V), a Vancouver-based company in which OPKO has made a strategic investment, reported topline results for its COSIRA trial assessing the efficacy and safety of the Neovasc ReducerTM, a novel percutaneous device for the treatment of refractory angina. The data shows that the Reducer achieved its primary endpoint, significantly improving the symptoms and functioning of patients disabled by previously untreatable refractory angina. The COSIRA trial also confirmed that the Reducer is safe and well-tolerated, with no reports of device-related serious adverse events. The safety and efficacy data from the randomized, controlled COSIRA trial is consistent with results seen in previous non-randomized pilot studies of the Reducer.
Neovasc Inc. Announces Publication of Positive Tiara™ Preclinical Data in the Journal JACC: Cardiovascular Interventions
PR Newswire - Tue Oct 29, 6:28AM CDT
Preclinical Studies Show Innovative Transcatheter Product to Treat Mitral Regurgitation is Safe, Technically Feasible and Results in a Well-Functioning Mitral Bioprosthesis-
Neovasc Inc. announces upcoming presentations at TCT 2013 scientific symposium
PR Newswire - Thu Oct 24, 6:28AM CDT
Neovasc's Tiara™ Program for the Transcatheter Treatment of Mitral Valve Disease Will Be Featured in Two Sessions
Neovasc Inc. reports financial results for second quarter of 2013
PR Newswire - Thu Aug 15, 6:28AM CDT
Year-over-Year Revenues Increased 71% from Robust Growth in Contract Manufacturing and Consulting Services Revenues--
Neovasc, an OPKO Investee, Reports Successful First Human Implant of Tiara(TM) Transcatheter Mitral Valve
Business Wire - Mon Feb 03, 8:16AM CST
OPKO Health, Inc. (NYSE:OPK), a multi-national biopharmaceutical and diagnostics company, today reported that Neovasc Inc. (TSXV:NVC), a Vancouver-based company in which OPKO has made a strategic investment, reported that a first-in-human implantation of its Tiara(TM) transcatheter mitral valve was successfully performed on January 30th by physicians at St. Paul's Hospital in Vancouver, BC. The transapical procedure resulted in the elimination of mitral regurgitation (MR) and significantly improved heart function in the patient, without the need for cardiac bypass support and with no procedural complications.
Neovasc receives first US patent for its novel Tiara(TM) transcatheter mitral valve replacement technology
PR Newswire - Wed Nov 13, 6:28AM CST
TSX Venture Exchange: NVC
Neovasc, an OPKO Supported Company, Reports That Reducer(TM) Achieves Primary Endpoint in COSIRA Trial, Significantly Improving Function in Patients with Refractory Angina
Business Wire - Wed Nov 06, 2:51PM CST
OPKO Health, Inc. (NYSE:OPK), a multi-national biopharmaceutical and diagnostics company, today reported that Neovasc Inc. (NVC.V), a Vancouver-based company in which OPKO has made a strategic investment, reported topline results for its COSIRA trial assessing the efficacy and safety of the Neovasc ReducerTM, a novel percutaneous device for the treatment of refractory angina. The data shows that the Reducer achieved its primary endpoint, significantly improving the symptoms and functioning of patients disabled by previously untreatable refractory angina. The COSIRA trial also confirmed that the Reducer is safe and well-tolerated, with no reports of device-related serious adverse events. The safety and efficacy data from the randomized, controlled COSIRA trial is consistent with results seen in previous non-randomized pilot studies of the Reducer.
Neovasc Inc. Announces Publication of Positive Tiara™ Preclinical Data in the Journal JACC: Cardiovascular Interventions
PR Newswire - Tue Oct 29, 6:28AM CDT
Preclinical Studies Show Innovative Transcatheter Product to Treat Mitral Regurgitation is Safe, Technically Feasible and Results in a Well-Functioning Mitral Bioprosthesis-
Neovasc Inc. announces upcoming presentations at TCT 2013 scientific symposium
PR Newswire - Thu Oct 24, 6:28AM CDT
Neovasc's Tiara™ Program for the Transcatheter Treatment of Mitral Valve Disease Will Be Featured in Two Sessions
Neovasc Inc. reports financial results for second quarter of 2013
PR Newswire - Thu Aug 15, 6:28AM CDT
Year-over-Year Revenues Increased 71% from Robust Growth in Contract Manufacturing and Consulting Services Revenues--
(0)
(0)